Comment
doi: 10.1200/JCO.2011.38.7167.
Epub 2011 Dec 12.
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials
Affiliations
- PMID: 22162582
- DOI: 10.1200/JCO.2011.38.7167
Item in Clipboard
Comment
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials
J Clin Oncol.
.
No abstract available
Comment on
-
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.J Clin Oncol. 2012 Jan 20;30(3):282-90. doi: 10.1200/JCO.2011.36.1360. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162589 Clinical Trial.
Similar articles
-
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21. Invest New Drugs. 2014. PMID: 24652201 Clinical Trial.
-
Benefit Mixed with Caution for Buparlisib.Cancer Discov. 2017 Feb;7(2):121. doi: 10.1158/2159-8290.CD-NB2016-161. Epub 2016 Dec 16. Cancer Discov. 2017. PMID: 27986714
-
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.Cancer Sci. 2014 Mar;105(3):347-53. doi: 10.1111/cas.12350. Epub 2014 Feb 13. Cancer Sci. 2014. PMID: 24405565 Free PMC article. Clinical Trial.
-
Benefits versus risk profile of buparlisib for the treatment of breast cancer.Expert Opin Drug Saf. 2019 Jul;18(7):553-562. doi: 10.1080/14740338.2019.1623877. Expert Opin Drug Saf. 2019. PMID: 31159599 Review.
-
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.Expert Opin Pharmacother. 2021 Feb;22(2):135-144. doi: 10.1080/14656566.2020.1825684. Epub 2020 Oct 30. Expert Opin Pharmacother. 2021. PMID: 33121281 Review.
Cited by
-
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Expert Rev Mol Diagn. 2012 Jul;12(6):593-602. doi: 10.1586/erm.12.59. Expert Rev Mol Diagn. 2012. PMID: 22845480 Free PMC article. Review.
-
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.Mol Cancer Ther. 2012 Jul;11(7):1609-17. doi: 10.1158/1535-7163.MCT-11-0996. Epub 2012 May 3. Mol Cancer Ther. 2012. PMID: 22556379 Free PMC article.
-
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.Int J Cancer. 2013 Jul;133(1):247-52. doi: 10.1002/ijc.27989. Epub 2013 Jan 15. Int J Cancer. 2013. PMID: 23238639 Free PMC article.
-
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.PLoS One. 2017 Jul 13;12(7):e0180263. doi: 10.1371/journal.pone.0180263. eCollection 2017. PLoS One. 2017. PMID: 28704425 Free PMC article.
-
Discovery of small molecule cancer drugs: successes, challenges and opportunities.Mol Oncol. 2012 Apr;6(2):155-76. doi: 10.1016/j.molonc.2012.02.004. Epub 2012 Mar 3. Mol Oncol. 2012. PMID: 22440008 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
